These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38876309)

  • 1. Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse.
    Morrison FG; Van Orden LJ; Zeitz K; Kuijer EJ; Smith SL; Heal DJ; Wallace TL
    Neuropharmacology; 2024 Oct; 257():110037. PubMed ID: 38876309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl increases dopamine release in rat nucleus accumbens: involvement of mesolimbic mu- and delta-2-opioid receptors.
    Yoshida Y; Koide S; Hirose N; Takada K; Tomiyama K; Koshikawa N; Cools AR
    Neuroscience; 1999; 92(4):1357-65. PubMed ID: 10426490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes.
    Onali P; Dedoni S; Olianas MC
    J Pharmacol Exp Ther; 2010 Jan; 332(1):255-65. PubMed ID: 19828880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
    Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
    Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
    Olianas MC; Concas D; Onali P
    Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvements of mu- and kappa-opioid receptors in morphine-induced antinociception in the nucleus accumbens of rats.
    Xiong W; Yu LC
    Neurosci Lett; 2006 May; 399(1-2):167-70. PubMed ID: 16490317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of opioid system in behavioral despair induced by social isolation stress in mice.
    Haj-Mirzaian A; Nikbakhsh R; Ramezanzadeh K; Rezaee M; Amini-Khoei H; Haj-Mirzaian A; Ghesmati M; Afshari K; Haddadi NS; Dehpour AR
    Biomed Pharmacother; 2019 Jan; 109():938-944. PubMed ID: 30551548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
    Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
    PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo neurochemical evidence that delta1-, delta2- and mu2-opioid receptors, but not mu1-opioid receptors, inhibit acetylcholine efflux in the nucleus accumbens of freely moving rats.
    Kiguchi Y; Aono Y; Watanabe Y; Yamamoto-Nemoto S; Shimizu K; Shimizu T; Kosuge Y; Waddington JL; Ishige K; Ito Y; Saigusa T
    Eur J Pharmacol; 2016 Oct; 789():402-410. PubMed ID: 27445235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
    Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
    ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.
    Ross NC; Reilley KJ; Murray TF; Aldrich JV; McLaughlin JP
    Br J Pharmacol; 2012 Feb; 165(4b):1097-108. PubMed ID: 21671905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
    Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
    J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General, kappa, delta and mu opioid receptor antagonists mediate feeding elicited by the GABA-B agonist baclofen in the ventral tegmental area and nucleus accumbens shell in rats: reciprocal and regional interactions.
    Miner P; Shimonova L; Khaimov A; Borukhova Y; Ilyayeva E; Ranaldi R; Bodnar RJ
    Brain Res; 2012 Mar; 1443():34-51. PubMed ID: 22305145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
    Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
    ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.